Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticalsis based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.
Key Features:
The first guide to market access for pharmaceuticals based on tested teaching materialsAddresses both pharmaceutical and vaccine productsIncludes case studies and scenariosCovers market access consdierations for Western Europe, the USA, Japan and ChinaExplains the impact the changing healthcare market will have on your productChapter 1:Health as a Good
Chapter 2: Decision-Making in Public Health
Chapter 3: Definition and Concepts
Chapter 4:HTA Decision Analysis framework
Chapter 5: Early HTA Advice
Chapter 6: Overview of Market Access Agreements
Chapter 7: External Reference Pricing
Chapter 8: Gap between Payers and Regulators
Chapter 9: Early Access Programs
Chapter 10: Market Access of Orphan Drugs
Chapter 11: Market Access of Vaccines in Developed Countries
Chapter 12: France
Chapter 13: Germany
Chapter 14: Italy
Chapter 15: Spain
![Introduction to Market Access for Pharmaceuticals [Paperback]](/itemImage/2/9/3/1/2_845538.jpg)